Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Monoamine oxidase inhibitors: a new generation.

Robinson DS.

Psychopharmacol Bull. 2002 Summer;36(3):124-38.

PMID:
12473970
2.

Transdermal selegiline: the new generation of monoamine oxidase inhibitors.

Patkar AA, Pae CU, Masand PS.

CNS Spectr. 2006 May;11(5):363-75. Review.

PMID:
16641841
3.

Transdermal selegiline.

Patkar AA, Pae CU, Zarzar M.

Drugs Today (Barc). 2007 Jun;43(6):361-77. Review.

PMID:
17612708
4.

Translating the evidence on atypical depression into clinical practice.

Hyman Rapaport M.

J Clin Psychiatry. 2007;68 Suppl 3:31-6. Review.

5.

Selegiline transdermal system: a novel treatment option for major depressive disorder.

Nandagopal JJ, DelBello MP.

Expert Opin Pharmacother. 2009 Jul;10(10):1665-73. doi: 10.1517/14656560903048942. Review.

PMID:
19527191
6.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Epub 2007 Jun 13. Review.

PMID:
17568687
7.

Current place of monoamine oxidase inhibitors in the treatment of depression.

Shulman KI, Herrmann N, Walker SE.

CNS Drugs. 2013 Oct;27(10):789-97. doi: 10.1007/s40263-013-0097-3. Review.

PMID:
23934742
8.

Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.

Thomas SJ, Shin M, McInnis MG, Bostwick JR.

Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Review.

PMID:
25884531
9.

A critical appraisal of the selegiline transdermal system for major depressive disorder.

Bied AM, Kim J, Schwartz TL.

Expert Rev Clin Pharmacol. 2015;8(6):673-81. doi: 10.1586/17512433.2016.1093416. Epub 2015 Oct 1. Review. Erratum in: Expert Rev Clin Pharmacol. 2016;9(2):339.

PMID:
26427518
10.

Selegiline transdermal system: current awareness and promise.

Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1153-63. Epub 2007 May 10. Review.

PMID:
17614182
11.

The transdermal delivery system of monoamine oxidase inhibitors.

VanDenBerg CM.

J Clin Psychiatry. 2012;73 Suppl 1:25-30. doi: 10.4088/JCP.11096su1c.04. Review.

12.

Monoamine oxidase inhibitors. A perspective on their use in the elderly.

Volz HP, Gleiter CH.

Drugs Aging. 1998 Nov;13(5):341-55. Review.

PMID:
9829163
13.

Monoamine oxidase inhibitors. An update on drug interactions.

Livingston MG, Livingston HM.

Drug Saf. 1996 Apr;14(4):219-27. Review.

PMID:
8713690
14.

Translating the evidence on atypical depression into clinical practice.

Rapaport MH, Thase ME.

J Clin Psychiatry. 2007 Apr;68(4):e11. Review.

15.
16.

Reversible monoamine oxidase-A inhibitors in resistant major depression.

Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.

Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Review.

PMID:
8313400
17.

MAO inhibitors: risks, benefits, and lore.

Wimbiscus M, Kostenko O, Malone D.

Cleve Clin J Med. 2010 Dec;77(12):859-82. doi: 10.3949/ccjm.77a.09103. Review.

18.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

19.

The current status of monoamine oxidase and its inhibitors.

Jarrott B, Vajda FJ.

Med J Aust. 1987 Jun 15;146(12):634-8. Review.

PMID:
3114597
20.
Items per page

Supplemental Content

Write to the Help Desk